Effects of mirthful laughter on growth hormone, IGF-1 and substance P in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 23, Issue 5, 2005, Pages 651-657

  Ishigami, Shin ^a   Nakajima, Atsuo ^a   Tanno, Makoto ^a   Matsuzaki, Tsuyoshi ^a   Suzuki, Hidenori ^a   Yoshino, Shinichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Growth hormone; Insulin like growth factor 1; Mirthful laughter; Rheumatoid arthritis; Stress; Substance P

Indexed keywords

GROWTH HORMONE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN C; SUBSTANCE P;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; JAPAN; LITERATURE; NEUROENDOCRINE SYSTEM; NONVERBAL COMMUNICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; STRESS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LAUGHTER; MIDDLE AGED; SUBSTANCE P;

EID: 24944486472     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. HUYSER B, PARKER JC: Stress and rheumatoid arthritis: an integrative review. Arthritis Care Res 1998; 11: 135-45.
2. PIKE JL, SMITH TL, HAUGER RL et al.: Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans. Psychosom Med 1997; 59: 447-57.
3. SPIEGEL D, BLOOM JR, KRAEMER HC, GOTTHEIL E: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989; 2: 888-91.
4. ZAUTRA AJ, HOFFMAN JM, MATT KS et al.: An examination of individual differences in the relationship between interpersonal stress and disease activity among women with rheumatoid arthritis. Arthritis Care Res 1998; 11: 271-9.
5. AFFLECK G, PFEIFFER C, TENNEN H, FIFIELD J: Attributional processes in rheumatoid arthritis patients. Arthritis Rheum 1987; 30: 927-31.
6. HARRINGTON L, AFFLECK G, URROWS S et al.: Temporal covariation of soluble interleukin-2 receptor levels, daily stress, and disease activity in rheumatoid arthritis. Arthritis Rheum 1993; 36: 199-203.
7. MUKAI E, NAGASHIMA M, HIRANO D, YOSHINO S: Comparative study of symptoms and neuroendocrine-immune network mediator levels between rheumatoid arthritis patients and healthy subjects. Clin Exp Rheumatol 2000; 18: 585-90.
8. COUSINS N: Anatomy of an illness (as perceived by the patient). N Engl J Med 1976; 295: 1458-63.
9. FRY WF Jr.: The physiologic effects of humor, mirth, and laughter. JAMA 1992; 267: 1857-8.
10. BERK LS, FELTEN DL, TAN SA, BITTMAN BB, WESTENGARD J: Modulation of neuroimmune parameters during the eustress of humor-associated mirthful laughter. Altern Ther Health Med 2001; 7: 62-72, 74-6.
11. BENNETT MP, ZELLER JM, ROSENBERG L, McCANN J: The effect of mirthful laughter on stress and natural killer cell activity. Altern Ther Health Med 2003; 9: 38-45.
12. NAKAJIMA A, HIRAI H, YOSHINO S: Reassessment of mirthful laughter in rheumatoid arthritis. J Rheumatol 1999; 26: 512-3.
13. YOSHINO S, MUKAI E: Neuroendocrine-immune system in patients with rheumatoid arthritis. Mod Rheumatol 2003; 13: 193-8.
14. YOSHINO S, FUJIMORI J, KOHDA M: Effects of mirthful laughter on neuroendocrine and immune systems in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 793-4.
15. LARSON PR, KRONENBERG HM, MELMED S, POLONSKY KS (eds.) Williams Textbook of Endocrinology. 10th ed. Philadelphia, Saunders: 2002: 219-43.
16. LIEB K, AHLVERS K, DANCKER K et al.: Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002; 27: 1041-9.
17. LEMBECK F: [Central transmission of afferent impulses. III. Incidence and significance of the substance P in the dorsal roots of the spinal cord.]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1953; 219: 197-213.
18. HARRISON S, GEPPETTI P: Substance p. Int J Biochem Cell Biol 2001; 33: 555-76.
19. McGILLIS JP, MITSUHASHI M, PAYAN DG: Immunomodulation by tachykinin neuropeptides. Ann N Y Acad Sci 1990; 594: 85-94.
20. PAYAN DG: Neuropeptides and inflammation: the role of substance P. Annu Rev Med 1989; 40: 341-52.
21. DORSHKIND K, HORSEMAN ND: The roles of prolactin, growth hormone, insulin-like growth factor-I and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000; 21: 292-312.
22. IMRICH R: The role of neuroendocrine system in the pathogenesis of rheumatic diseases (minireview). Endocr Regul 2002; 36: 95-106.
23. WALLIS M: Growth hormone: deletions in the protein and introns in the gene. Nature 1980; 284: 512.
24. MORIKAWA M, NIXON T, GREEN H: Growth hormone and the adipose conversion of 3T3 cells. Cell 1982; 29: 783-9.
25. NIXON BT, GREEN H: Growth hormone promotes the differentiation of myoblasts and preadipocytes generated by azacytidine treatment of 10T1/2 cells. Proc Natl Acad Sci USA 1984; 81: 3429-32.
26. WIEDERMANN CJ, REINISCH N, KAHLER C et al.: In vivo activation of circulating monocytes by exogenous growth hormone in man. Brain Behav Immun 1992; 6: 387-93.
27. EDWARDS CK, 3rd, GHIASUDDIN SM, YUNGER LM et al.: In vivo administration of recombinant growth hormone or gamma interferon activates macrophages: enhanced resistance to experimental Salmonella typhimurium infection is correlated with generation of reactive oxygen intermediates. Infect Immun 1992; 60: 2514-21.
28. GEFFNER ME, BERSCH N, LIPPE BM, ROSENFELD RG, HINTZ RL, GOLDE DW: Growth hormone mediates the growth of T-lymphoblast cell lines via locally generated insulin-like growth factor-1. J Clin Endocrinol Metab 1990; 71: 464-9.
29. INOUE T, SAITO H, FUKUSHIMA R et al.: Growth hormone and insulin like growth factor I enhance host defense in a murine sepsis model. Arch Surg 1995; 130: 1115-22.
30. EDWARDS CK, 3rd, LORENCE RM, DUNHAM DM et al.: Hypophysectomy inhibits the synthesis of tumor necrosis factor alpha by rat macrophages: partial restoration by exogenous growth hormone or interferon gamma. Endocrinology 1991; 128: 989-86.
31. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
32. LORISH CD, MAISIAK R: The Face Scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 1986; 29: 906-9.
33. DOWNIE WW, LEATHAM PA, RHIND VM, WRIGHT V, BRANCO JA, ANDERSON JA: Studies with pain rating scales. Ann Rheum Dis 1978; 37: 378-81.
34. FEHDER WP, HO WZ, CAMPBELL DE et al.: Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay. Clin Diagn Lab Immunol 1998; 5: 303-7.
35. DENKO CW, BOJA B, MOSKOWITZ RW: Growth factors, insulin-like growth factor-1 and growth hormone, in synovial fluid and serum of patients with rheumatic disorders. Osteoarthritis Cartilage 1996; 4: 245-9.
36. SHIRATSUCHI M, OKAJIMA T, INOUE K, TAKAHASHI T, YAMAMOTO M, SAKAI K: A case of abnormal growth hormone secretion possibly caused by low somatomedin production of unknown origin: is the unresponsiveness of GH receptor responsible for it? Endocrine J 1996; 43 (Suppl.): S85-7.
37. SVENSON KL, LUNDQVIST G, WIDE L, HALLGREN R: Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987; 36: 940-3.
38. TEMPL E, KOELLER M, RIEDL M, WAGNER O, GRANINGER W, LUGER A: Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. Br J Rheumatol 1996; 35: 350-6.
39. ESPINOZA LR, ESPINOZA CG, CUELLAR ML, SCOPELITIS E, SILVEIRA LH, GROTENDORST GR: Fibroblast function in psoriatic arthritis. II. Increased expression of beta platelet derived growth factor receptors and increased production of growth factor and cytokines. J Rheumatol 1994; 21: 1507-11.
40. ANASTASSIADES TP, LEY J, WOOD A, IRWIN D: The growth kinetics of synovial fibroblastic cells from inflammatory and noninflammatory arthropathies. Arthritis Rheum 1978; 21: 461-6.
41. LEMMEY A, MADDISON P, BRESLIN A et al.: Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis. J Rheumatol 2001; 28: 29-34.
42. FERNIHOUGH JK, BILLINGHAM ME, CWYFAN-HUGHES S, HOLLY JM: Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum 1996; 39: 1556-65.
43. JOHANSSON AG, BAYLINK DJ, af EKENSTAM E, LINDH E, MOHAN S, LJUNGHALL S: Circulating levels of insulin-like growth factor-I and -II, and IGF-binding protein-3 in inflammation and after parathyroid hormone infusion. Bone Miner 1994; 24: 25-31.
44. FAN J, CHAR D, BAGBY GJ, GELATO MC, LANG CH: Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995; 269: R1204-12.
45. FAN J, WOJNAR MM, THEODORAKIS M, LANG CH: Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol 1996; 270: R621-9.
46. DE BENEDETTI F, ALONZI T, MORETTA A et al.: Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-50.
47. STOUT SC, OWENS MJ, NEMEROFF CB: Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 2001; 41: 877-906.
48. RUPNIAK NM, KRAMER MS: Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485-90.
49. KEEBLE JE, BRAIN SD: A role for substance P in arthritis? Neurosci Lett 2004; 361: 176-9.
50. KATO Y, CHIHARA K, OHGO S, IWASAKI Y, ABE H, IMUR H: Growth hormone and prolactin release by substance P in rats. Life Sci 1976; 19: 441-6.
51. RIVIER C, BROWN M, VALE W: Effect of neurotensin, substance P and morphine sulfate on the secretion of prolactin and growth hormone in the rat. Endocrinology 1977; 100: 751-4.
52. COVIC T, ADAMSON B, HOUGH M: The impact of passive coping on rheumatoid arthritis pain. Rheumatology (Oxford) 2000; 39: 1027-30.
53. ISHII H, NAGASHIMA M, TANNO M, NAKAJIMA A, YOSHINO S: Does being easily moved to tears as a response to psychological stress reflect response to treatment and the general prognosis in patients with rheumatoid arthritis? Clin Exp Rheumatol 2003; 21: 611-6.